Leonardo Faoro

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.

C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Protein kinase C beta in malignant pleural mesothelioma.

Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma.

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

MET receptor tyrosine kinase.

MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.

Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non-Small-Cell Lung Cancer, A Phase II Trial.